Christian Sindu J, Boama Vincent, Satti Hiba, Ramawat Joohi, Elhadd Tarik A, Ashawesh Khaled, Dukhan Khaled, Beer Stephen
Department of Obstetrics and Gynecology, Al Wakra Hospital, Hamad Medical Corporation, PO Box 82228, Doha, Qatar.
Department of Obstetrics and Gynecology, Sidra Medical and Research Center, PO box 26999, Doha, Qatar.
BMC Res Notes. 2018 Jul 3;11(1):426. doi: 10.1186/s13104-018-3540-1.
The debate still continues about the preferred modality of treatment of gestational diabetes requiring pharmacological treatment. Insulin was previously considered as the gold standard, but the National Institute of Health and Care Excellence now recommend metformin as the first line drug of choice. The pharmacological management of gestational diabetes mellitus in the Middle East with its high risk population has not been widely published. We aim to evaluate the safety and efficacy of using metformin in comparison to insulin, in our group of patients, and to study key associated morbidities.
A total of 291 women registered in the clinic during the study period. One hundred and twenty-one (121) were women with gestational diabetes Mellitus requiring medical therapy. Among them, 107 delivered at term. Ninety (84%) women received metformin. Additional insulin was required in 32% of these patients. There was a significant difference in the birth weight of babies in the metformin with insulin group of 207 g (p value 0.04) in favour of metformin. There was no significant difference in maternal or neonatal morbidities between the groups. Metformin was thus found to be a safe, practical and cost effective medication to be offered to our population.
关于需要药物治疗的妊娠期糖尿病的首选治疗方式的争论仍在继续。胰岛素曾被视为金标准，但英国国家卫生与临床优化研究所现在推荐二甲双胍作为一线首选药物。中东地区高危人群妊娠期糖尿病的药物治疗尚未广泛发表。我们旨在评估在我们的患者群体中，与胰岛素相比，使用二甲双胍的安全性和有效性，并研究关键的相关发病率。
在研究期间，共有291名女性在诊所登记。其中121名是需要药物治疗的妊娠期糖尿病女性。其中，107名足月分娩。90名（84%）女性接受了二甲双胍治疗。这些患者中有32%需要额外使用胰岛素。二甲双胍联合胰岛素组婴儿出生体重有207克的显著差异（p值0.04），有利于二甲双胍。两组之间的母体或新生儿发病率没有显著差异。因此，发现二甲双胍是一种安全、实用且具有成本效益的药物，可提供给我们的人群。
